Blog

A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Established Cardiovascular Disease

Conditions: Obesity or Overweight; Cardiovascular Disease
Interventions: Combination Product: Petrelintide; Combination Product: Placebo
Sponsors: Hoffmann-La Roche; Zealand Pharma
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

October 8, 2026Comments OffCardiology | Cardiology Clinical Trials | Cardiology Studies | ClinicalTrials.gov | Drug Trials Near Me | US National Library of Medicine
Read more 
Enzalutamide for Patients With Androgen Receptor Positive Salivary Cancers
Conditions: Androgen Receptor Positive; Locally Advanced Salivary Gland Carcinoma; Metastatic Salivary Gland Carcinoma; Salivary Duct Carcinoma; Salivary Gland Adenocarcinoma, NOS; Salivary Gland Basal Cell Adenocarcinoma; Stage III Major Salivary Gland Cancer AJCC v7

Interventions: Drug: enzalutamide

Sponsors: Alliance for Clinical Trials in Oncology; National Cancer Institute (NCI); Astellas Pharma US, Inc.

Active, not **RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

October 8, 2026Comments OffClinicalTrials.gov | Gastroenterology Clinical Trials | Gastroenterology Studies | US National Library of Medicine
Read more 
Tracking Income Dynamics and Everyday Health Study

Conditions: HIV; Hypertension; Hypercholerolemia; Type 2 Diabetes
Interventions: Other: Preventative health review invitation early in SNAP cycle; Other: Financial counseling invitation early in the SNAP cycle; Other: Aim 3 follow-up call early in the SNAP period; Other: Preventative health review invitation late in SNAP cycle; Other: Financial counseling invitation late in the SNAP cycle; Other: Aim 3 follow-up call late in the SNAP cycle
Sponsors: University of Pennsylvania; National Institute on Aging (NIA)
Not yet **RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

October 8, 2026Comments OffClinicalTrials.gov | Endocrinology Clinical Trials | Endocrinology Studies | US National Library of Medicine
Read more 
Evaluation of MiniMed Next Generation Extended Wear Sensors and Algorithm in Patients With Type 1 and Type 2 Diabetes

Conditions: Type 1 Diabetes; Type 2 Diabetes
Interventions: Device: Next Generation Extended Wear Sensors
Sponsors: Medtronic MiniMed, Inc.
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

October 8, 2026Comments OffClinicalTrials.gov | Endocrinology Clinical Trials | Endocrinology Studies | US National Library of Medicine
Read more 
A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes

Conditions: Obesity or Overweight; Type 2 Diabetes
Interventions: Combination Product: Petrelintide; Combination Product: Placebo
Sponsors: Hoffmann-La Roche; Zealand Pharma
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

October 8, 2026Comments OffClinicalTrials.gov | Endocrinology Clinical Trials | Endocrinology Studies | US National Library of Medicine
Read more 
Continuous Delivery of Ranibizumab Via the Port Delivery System for Proliferative Diabetic Retinopathy-related Vitreous Hemorrhage With Pars Plana Vitrectomy and Limited PRP.

Conditions: Proliferative Diabetic Retinopathy (DR); Vitrectomy; Diabetic Retinopathy (DR); Diabetes (DM)
Interventions: Device: PDS Implant filled with 100 mg/mL Ranibizumab; Drug: Ranibizumab
Sponsors: Southeast Retina Center, Georgia; Genentech, Inc.
Not yet **RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

October 8, 2026Comments OffClinicalTrials.gov | Endocrinology Clinical Trials | Endocrinology Studies | US National Library of Medicine
Read more 
Intermediate-Size Cohort EAP for Ersodetug in Patients With Inadequately Controlled Hypoglycemia Related to a Tumor

Conditions: Tumor-associated Hyperinsulinism (Tumor HI)
Interventions: Drug: Ersodetug (9 mg/kg) + SOC
Sponsors: Rezolute
Available

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

October 8, 2026Comments OffClinicalTrials.gov | Endocrinology Clinical Trials | Endocrinology Studies | US National Library of Medicine
Read more 
Keratinized Tissue Augmentation Using Augmented Gingival Matrix Compared to Free Gingival Graft Around Implants
Conditions: Keratinized Tissue Augmentation Around Dental Implants

Interventions: Device: Augmented Gingival Matrix graft; Procedure: Free Gingival Graft

Sponsors: The Forsyth Institute

Not yet **RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

October 8, 2026Comments OffClinicalTrials.gov | Dental Studies | Oncology Clinical Trials | US National Library of Medicine
Read more 
US/PA/E Imaging for Early Identification of Tumor Response in Patients With Stage II-III Triple Negative Breast Cancer Receiving Neoadjuvant Immunotherapy and Chemotherapy
Conditions: Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage III Breast Cancer AJCC v8; Triple-Negative Breast Carcinoma

Interventions: Procedure: Elastography; Procedure: Magnetic Resonance Imaging; Procedure: Photoacoustic Imaging; Procedure: Ultrasound Imaging; Drug: Pembrolizumab; Drug: Carboplatin; Drug: Paclitaxel; Drug: Doxorubicin; Drug: Cyclophosphamide

Sponsors: Emory University; National Cancer Institute (NCI)

Not yet **RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

October 8, 2026Comments OffClinicalTrials.gov | Oncology Clinical Trials | Oncology Studies | US National Library of Medicine
Read more 
The CLASP III TR CED Study

Conditions: Tricuspid Regurgitation; Heart Valve Diseases; Heart Diseases; Cardiovascular Diseases; Tricuspid Valve Insufficiency
Interventions: Device: PASCAL Precision system Treated; Other: Medicare Eligible Untreated Patients
Sponsors: Edwards Lifesciences
Not yet **RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

October 7, 2026Comments OffCardiology | Cardiology Clinical Trials | Cardiology Studies | ClinicalTrials.gov | Drug Trials Near Me | US National Library of Medicine
Read more